State of New Jersey Common Pension Fund D Sells 7,497 Shares of Elanco Animal Health Incorporated $ELAN

State of New Jersey Common Pension Fund D decreased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 4.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 177,037 shares of the company’s stock after selling 7,497 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Elanco Animal Health were worth $2,528,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allworth Financial LP boosted its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after buying an additional 2,090 shares during the period. Wealthquest Corp acquired a new stake in Elanco Animal Health in the 1st quarter worth about $56,000. Caitong International Asset Management Co. Ltd raised its stake in Elanco Animal Health by 261.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after purchasing an additional 2,922 shares in the last quarter. Covestor Ltd raised its stake in Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company’s stock worth $74,000 after purchasing an additional 5,927 shares in the last quarter. Finally, MRP Capital Investments LLC raised its stake in Elanco Animal Health by 60.0% in the 1st quarter. MRP Capital Investments LLC now owns 8,000 shares of the company’s stock worth $84,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective for the company in a research note on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Elanco Animal Health in a research note on Wednesday, October 8th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Elanco Animal Health Price Performance

ELAN stock opened at $22.13 on Wednesday. The company has a 50 day simple moving average of $19.50 and a 200 day simple moving average of $15.45. The stock has a market cap of $10.99 billion, a price-to-earnings ratio of 25.73, a P/E/G ratio of 4.09 and a beta of 1.65. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $22.45. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.